We graded expression of VEGF-A , VEGF-B , VEGF-C , VEGF-D , VEGF-R@ , and VEGF-R@ to assess whether overexpression predicted bevacizumab resistance in samples from @ of @ patients randomised to capecitabine ( C ) , capecitabine and bevacizumab ( CB ) , or CB and mitomycin ( CBM ) in the MAX trial and extended the analysis to the CAIRO-@ population .